Business Context and Reporting Period
Company: Arrowhead Research Corporation (Arrowhead)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2010
Business Model: Arrowhead is a development-stage nanomedicine company that operates through a portfolio of majority-owned subsidiaries (Calando Pharmaceuticals, Ablaris Therapeutics, and Unidym) and minority investments (Nanotope, Leonardo). The company focuses on preclinical and clinical development of therapeutics for cancer, obesity, and tissue regeneration.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2010 | Three Months Ended Dec 31, 2009 |
|---|---|---|
| Revenue | $4,994,969 | $148,068 |
| Net Loss (Attributable to Arrowhead) | $(1,437,682) | $(1,544,927) |
| Operating Loss | $(1,009,317) | $(2,160,218) |
| Cash and Cash Equivalents (Ending) | $5,466,804 | $3,809,596 |
| Net Cash Used in Operating Activities | $(1,423,637) | $(1,617,843) |
| Total Assets | $15,189,763 | $12,354,542 (Sep 30, 2010) |
| Total Current Liabilities | $7,901,951 | $4,276,246 (Sep 30, 2010) |
| Derivative Liability | $1,943,252 | $2,408,522 (Sep 30, 2010) |
Note: The filing does not provide a specific "profit margin" as the company is in a development stage with significant losses. Revenue increased significantly due to specific licensing transactions.
Material Changes vs. Prior Period
- Revenue Surge: Revenue increased from $148,068 to $4,994,969 (a 3,273% increase). This was primarily driven by $4.5 million in revenue recorded by subsidiary Unidym from three agreements with Samsung Electronics, alongside recurring revenue from CNT sales and grant revenue from Calando.
- Expense Increases:
- Research & Development (R&D): Increased from $277,788 to $3,509,458. The increase was largely due to $2 million in licensing fees to the University of Texas and $1.2 million in license fees to universities related to the Samsung transaction.
- General & Administrative (G&A): Increased from $746,250 to $1,128,957, driven by professional services ($647,000) related to the Samsung transaction and patent expenses ($206,000).
- Other Income: Shifted from a net expense of $(70,444) to income of $517,434. This was primarily due to a non-cash gain of $465,270 from the change in fair value of a derivative liability.
- Liquidity: Cash decreased by approximately $1.4 million during the quarter due to operational spending, despite the revenue spike. Trade receivables increased significantly to $4.59 million, reflecting the Samsung revenue recognition.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management anticipates satisfying cash requirements for at least the next twelve months with current resources ($5.5 million). However, further equity financings, asset sales, or license agreements will be necessary to fund future operations.
- Strategic Shifts:
- Unidym Sale: In January 2011 (subsequent event), Arrowhead sold its ownership interest in Unidym to Wisepower Co., Ltd. This sale includes $5 million in immediate consideration and up to $140 million in contingent consideration based on revenue milestones. Cash burn associated with Unidym ceased in mid-January 2011.
- Calando Restructuring: In January 2011, Arrowhead converted approximately $8.1 million of debt owed by Calando into preferred stock.
- Ablaris Funding: In January 2011, subsidiary Ablaris raised approximately $1.7 million in Series A Preferred Stock.
- Risks and Contingencies:
- NASDAQ Compliance: The company received a deficiency letter from NASDAQ regarding the minimum bid price requirement (stock traded below $1.00 for 30 consecutive days). The company has a 180-day grace period to regain compliance.
- Debt Obligations: Calando has a $500,000 unsecured convertible promissory note that matured in November 2010 and has been temporarily extended while terms are negotiated.
- Derivative Liability: The company carries a significant derivative liability ($1.94 million) related to antidilution provisions in warrants issued in June 2010, which is marked-to-market quarterly.
Investor Verification Checklist
- Revenue Quality: Verify the collectability of the $4.59 million in trade receivables, as a significant portion is tied to the Samsung transaction and may be subject to future adjustments or payment delays.
- Unidym Sale Terms: Review the definitive merger agreement with Wisepower to understand the probability of achieving the $140 million in contingent revenue milestones.
- Derivative Liability Volatility: Monitor the fair value of the $1.94 million derivative liability, as fluctuations in stock price will directly impact non-cash gains or losses in future quarters.
- NASDAQ Status: Track the stock price to ensure it meets the $1.00 minimum bid price requirement within the 180-day grace period to avoid delisting.
- Calando Debt Resolution: Confirm the final terms of the $500,000 convertible note extension to assess potential dilution or cash outflow risks.